Laboratory Corporation of America Holdings

NYSE LH

Download Data

Laboratory Corporation of America Holdings Sales to Operating Cash Flow Ratio 5 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024

Laboratory Corporation of America Holdings Sales to Operating Cash Flow Ratio 5 year CAGR is NA for the Trailing 12 Months (TTM) ending March 31, 2024. Sales to operating cash flow ratio measures the revenue generated by a company relative to its operating cash flow. It is calculated by dividing the revenue by the operating cash flow. This ratio provides insights into the efficiency of revenue generation compared to the company's operating cash flow. A higher sales to operating cash flow ratio suggests better revenue generation efficiency. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Laboratory Corporation of America Holdings Sales to Operating Cash Flow Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 13.22, a 76.63% change year over year.
  • Laboratory Corporation of America Holdings Sales to Operating Cash Flow Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 7.49, a 37.27% change year over year.
  • Laboratory Corporation of America Holdings Sales to Operating Cash Flow Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 5.45, a -40.77% change year over year.
  • Laboratory Corporation of America Holdings Sales to Operating Cash Flow Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was 9.21, a -11.48% change year over year.
NYSE: LH

Laboratory Corporation of America Holdings

CEO Mr. Adam H. Schechter
IPO Date March 29, 1990
Location United States
Headquarters 358 South Main Street, Burlington, NC, United States, 27215
Employees 67,000
Sector Healthcare
Industry Diagnostics & research
Description

Labcorp Holdings Inc. operates as a laboratory services company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers.

Similar companies

WAT

Waters Corporation

NA

NA

HOLX

Hologic Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email